Literature DB >> 26125141

Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012.

Linnet Masese1, Jared M Baeten, Barbra A Richardson, Elizabeth Bukusi, Grace John-Stewart, Susan M Graham, Juma Shafi, James Kiarie, Julie Overbaugh, R Scott McClelland.   

Abstract

OBJECTIVE: The objective of this study was to understand temporal trends in the contribution of different genital tract infections to HIV incidence over 20 years of follow-up in a cohort of high-risk women.
DESIGN: A prospective cohort study.
METHODS: We performed monthly evaluations for HIV, vaginal yeast, bacterial vaginosis, Trichomonas vaginalis, Neisseria gonorrhoeae, nonspecific cervicitis, herpes simplex virus type two (HSV-2), genital ulcer disease (GUD) and genital warts. We used Cox regression to evaluate the association between sexually transmitted infections (STIs) and HIV acquisition over four time periods (1993-1997, 1998-2002, 2003-2007, 2008-2012). Models were adjusted for age, workplace, sexual risk behaviour, hormonal contraceptive use and other STIs. The resulting hazard ratios were used to calculate population attributable risk percentage (PAR%).
RESULTS: Between 1993 and 2012, 1964 women contributed 6135 person-years of follow-up. The overall PAR% for each infection was prevalent HSV-2 (48.3%), incident HSV-2 (4.5%), bacterial vaginosis (15.1%), intermediate microbiota (7.5%), vaginal yeast (6.4%), T. vaginalis (1.1%), N. gonorrhoeae (0.9%), nonspecific cervicitis (0.7%), GUD (0.8%) and genital warts (-0.2%). Across the four time periods, the PAR% for prevalent HSV-2 (40.4%, 61.8%, 58.4%, 48.3%) and bacterial vaginosis (17.1%, 19.5%, 14.7%, 17.1%) remained relatively high and had no significant trend for change over time. The PAR% for trichomoniasis, gonorrhoea, GUD and genital warts remained less than 3% across the four periods.
CONCLUSION: Bacterial vaginosis and HSV-2 have consistently been the largest contributors to HIV acquisition risk in the Mombasa Cohort over the past 20 years. Interventions that prevent these conditions would benefit women's health and could reduce their risk of becoming infected with HIV.

Entities:  

Mesh:

Year:  2015        PMID: 26125141      PMCID: PMC4576156          DOI: 10.1097/QAD.0000000000000646

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  35 in total

Review 1.  Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials.

Authors:  H Grosskurth; R Gray; R Hayes; D Mabey; M Wawer
Journal:  Lancet       Date:  2000-06-03       Impact factor: 79.321

2.  Syndromic treatment of sexually transmitted diseases reduces the proportion of incident HIV infections attributable to these diseases in rural Tanzania.

Authors:  K K Orroth; A Gavyole; J Todd; F Mosha; D Ross; E Mwijarubi; H Grosskurth; R J Hayes
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

3.  Antibiotic chemoprophylaxis and HIV infection in Kenyan sex workers.

Authors:  Richard Steen; Gina Dallabetta; Graham Neilsen
Journal:  JAMA       Date:  2004-08-25       Impact factor: 56.272

4.  Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.

Authors:  Joshua T Schiffer; David A Swan; Lawrence Corey; Anna Wald
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

5.  Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases and treatable symptomatic sexually transmitted diseases in Rakai District, Uganda. Rakai Project Team.

Authors:  R H Gray; M J Wawer; N K Sewankambo; D Serwadda; C Li; L H Moulton; T Lutalo; F Wabwire-Mangen; M P Meehan; S Ahmed; L A Paxton; N Kiwanuka; F Nalugoda; E L Korenromp; T C Quinn
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

6.  Randomized Trial of Periodic Presumptive Treatment With High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women.

Authors:  R Scott McClelland; Jennifer E Balkus; Jeannette Lee; Omu Anzala; Joshua Kimani; Jane Schwebke; Vivian Bragg; Shelly Lensing; Lale Kavak
Journal:  J Infect Dis       Date:  2014-12-19       Impact factor: 5.226

7.  Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.

Authors:  A Wald; J Zeh; S Selke; T Warren; A J Ryncarz; R Ashley; J N Krieger; L Corey
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

8.  Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials.

Authors:  J M Baeten; B A Richardson; H L Martin; P M Nyange; L Lavreys; E N Ngugi; K Mandaliya; J O Ndinya-Achola; J J Bwayo; J K Kreiss
Journal:  J Acquir Immune Defic Syndr       Date:  2000-08-15       Impact factor: 3.731

Review 9.  Chancroid: clinical manifestations, diagnosis, and management.

Authors:  D A Lewis
Journal:  Sex Transm Infect       Date:  2003-02       Impact factor: 3.519

10.  Incident herpes simplex virus type 2 infection increases the risk of subsequent episodes of bacterial vaginosis.

Authors:  Linnet Masese; Jared M Baeten; Barbra A Richardson; Elizabeth Bukusi; Grace John-Stewart; Walter Jaoko; Juma Shafi; James Kiarie; R Scott McClelland
Journal:  J Infect Dis       Date:  2013-11-22       Impact factor: 5.226

View more
  35 in total

Review 1.  Vaginal microbiota and susceptibility to HIV.

Authors:  McKenna C Eastment; R Scott McClelland
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

2.  Associations between vaginal bacteria implicated in HIV acquisition risk and proinflammatory cytokines and chemokines.

Authors:  Michelle C Sabo; Dara A Lehman; Bingjie Wang; Barbra A Richardson; Sujatha Srinivasan; Lusi Osborn; Daniel Matemo; John Kinuthia; Tina L Fiedler; Matthew M Munch; Alison L Drake; David N Fredricks; Julie Overbaugh; Grace John-Stewart; R Scott McClelland; Susan M Graham
Journal:  Sex Transm Infect       Date:  2019-06-13       Impact factor: 3.519

3.  Elevated Risk of Bacterial Vaginosis Among Users of the Copper Intrauterine Device: A Prospective Longitudinal Cohort Study.

Authors:  Kathryn Peebles; Flavia M Kiweewa; Thesla Palanee-Phillips; Catherine Chappell; Devika Singh; Katherine E Bunge; Logashvari Naidoo; Bonus Makanani; Nitesha Jeenarain; Doerieyah Reynolds; Sharon L Hillier; Elizabeth R Brown; Jared M Baeten; Jennifer E Balkus
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

Review 4.  The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.

Authors:  Jennifer Velloza; Renee Heffron
Journal:  Curr HIV/AIDS Rep       Date:  2017-10       Impact factor: 5.071

5.  Association of Recent Bacterial Vaginosis With Acquisition of Mycoplasma genitalium.

Authors:  Erica M Lokken; Jennifer E Balkus; James Kiarie; James P Hughes; Walter Jaoko; Patricia A Totten; R Scott McClelland; Lisa E Manhart
Journal:  Am J Epidemiol       Date:  2017-07-15       Impact factor: 4.897

Review 6.  Genital inflammation, immune activation and risk of sexual HIV acquisition.

Authors:  Jo-Ann S Passmore; Heather B Jaspan; Lindi Masson
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

7.  Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Tarek Hamouda; Derek A Pullum; Gary Cohen; Vira Bitko; Ali Fattom
Journal:  Vaccine       Date:  2019-09-09       Impact factor: 3.641

8.  Associations of the vaginal microbiota with HIV infection, bacterial vaginosis, and demographic factors.

Authors:  Christel Chehoud; Daniel J Stieh; Aubrey G Bailey; Alice L Laughlin; Shannon A Allen; Kerrie L McCotter; Scott A Sherrill-Mix; Thomas J Hope; Frederic D Bushman
Journal:  AIDS       Date:  2017-04-24       Impact factor: 4.177

9.  Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study.

Authors:  R Scott McClelland; Jairam R Lingappa; Sujatha Srinivasan; John Kinuthia; Grace C John-Stewart; Walter Jaoko; Barbra A Richardson; Krista Yuhas; Tina L Fiedler; Kishorchandra N Mandaliya; Matthew M Munch; Nelly R Mugo; Craig R Cohen; Jared M Baeten; Connie Celum; Julie Overbaugh; David N Fredricks
Journal:  Lancet Infect Dis       Date:  2018-01-26       Impact factor: 25.071

10.  Gender-Based Violence, Physiological Stress, and Inflammation: A Cross-Sectional Study.

Authors:  Madeleine Heller; Sarah T Roberts; Linnet Masese; Jacquiline Ngina; Neha Chohan; Vrasha Chohan; Juma Shafi; R Scott McClelland; Eleanor Brindle; Susan M Graham
Journal:  J Womens Health (Larchmt)       Date:  2018-04-09       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.